Analyst Expectations for Halozyme Therapeutics's Future
Portfolio Pulse from Benzinga Insights
Halozyme Therapeutics (NASDAQ:HALO) has received mostly bullish ratings from analysts in the last quarter, with an average price target of $58.14, indicating a potential upside from the current price of $37.13. The average price target has increased by 6.35% from the previous average of $54.67.
October 09, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Halozyme Therapeutics has received mostly bullish ratings from analysts, indicating a potential upside.
The bullish ratings and increased price target suggest that analysts believe the stock has potential for growth. This could lead to increased investor interest and a potential increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100